The Allurion Balloon, a swallowable gastric balloon, combined with daily subcutaneous injections of liraglutide has been found to lead to a significant average total body weight loss of 19% (18kg or 40lb) after around four months in people with obesity.
The Allurion is the world’s first and only swallowable gastric balloon placed without surgery, endoscopy, or anesthesia, and is excreted naturally after around 16 weeks. It has been found to deliver weight loss in individuals with overweight and obesity without going under the knife, while liraglutide has the potential to further safely enhance weight loss in cases of suboptimal adherence with the program. The two treatment approaches appear to have complementary mechanisms of action.
“The combination therapy [balloon and liraglutide] resulted in an additional weight loss compared to the two single treatments,” said Roberta Ienca, MD, from the Clinica Nuova Villa Claudia, Rome, Italy. “Despite both the balloon and liraglutide working on the early satiety feeling, the introduction of liraglutide around one month after [swallowing the balloon] or more frequently after three to four months, could sustain these feelings for a longer period of time.”
The balloon stayed inside participants’ stomachs for an average of 16 weeks and liraglutide was continued for an average of four months, resulting in a mean reduction in body mass index (BMI) of 6.4kg/m2.
To read more, CLICK HERE.
